Bone marrow mesenchymal stromal cells with support of bispecific antibody and ultrasound-mediated microbubbles prevent myocardial fibrosis via the signal transducer and activators of transcription signaling pathway

Cytotherapy

Volumn 13, Issue 4, 2011, Pages 431-440

  Deng, Wei ^a   Chen, Qing Wei ^a   Li, Xing Sheng ^a   Liu, Hao ^a   Niu, Si Qiang ^a   Zhou, Yue ^a   Li, Gui Qiong ^a   Ke, Da Zhi ^a   Mo, Xian Gang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

bispecifi c antibody; mesenchymal stromal cell transplantation; microbubbles; myocardial fi brosis; signal transducer and activators of transcription

Indexed keywords

BISPECIFIC ANTIBODY; CD29 ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE B; MESSENGER RNA; MYOSIN LIGHT CHAIN ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; TESTIS DETERMINING FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW MESENCHYMAL STROMAL CELL; BONE MARROW MESENCHYMAL STROMAL CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL HOMING; DOWN REGULATION; ECHOGRAPHY; FEMALE; FLOW CYTOMETRY; HEART MUSCLE; HEART MUSCLE FIBROSIS; MALE; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 79952643815     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.542458     Document Type: Article

References (47)

1. Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy. 2009;11: 503-15.
2. Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA. 1995;92:4857-61.
3. Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niibe K, Hiratsu E, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med. 2009;206:2483-96.
4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Mnimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7. (Pubitemid 44269669)
5. Lee RJ, Fang Q, Davol PA, Gu Y, Sievers RE, Grabert RC, et al. Antibody targeting of stem cells to infarcted myocardium. Stem Cells. 2007;25:712-7. (Pubitemid 46357399)
6. + tumors. J Hematother Stem Cell Res. 2001;10:247-60. (Pubitemid 32423549)
7. Xu YL, Gao YH, Liu Z, Tan KB, Hua X, Fang ZQ, et al. Myocardium-targeted transplantation of mesenchymal stem cells by diagnostic ultrasound-mediated microbubble destruction improves cardiac function in myocardial infarction of New Zealand rabbits. Int J Cardiol. 2010;138:182-95.
8. Zhang Q, Wang Z, Ran H, Fu X, Li X, Zheng Y, et al. Enhanced gene delivery into skeletal muscles with ultrasound and microbubble techniques. Acad Radiol. 2006;13:363-7. (Pubitemid 43247857)
9. Li X, Wang Z, Ran H, Yuan Q, Zheng Y, Ren J, et al. Experimental research on therapeutic angiogenesis induced by hepatocyte growth factor directed by ultrasound-targeted microbubble destruction in rats. J Ultrasound Med. 2008;27:453-60. (Pubitemid 351428128)
10. Wang ZX, Wang ZG, Ran HT, Ren JL, Zhang Y, Li Q, et al. The treatment of liver fibrosis induced by hepatocyte growth factor-directed, ultrasound-targeted microbubble destruction in rats. Clin Imaging. 2009;33:454-61.
11. Ren JL, Wang ZG, Zhang Y, Zheng YY, Li XS, Zhang QX, et al. Transfection efficiency of TDL compound in HUVEC enhanced by ultrasound-targeted microbubble destruction. Ultrasound Med Biol. 2008;34:1857-67.
12. Luo J, Zhou X, Diao L, Wang Z. Experimental research on wild-type p53 plasmid transfected into retinoblastoma cells and tissues using an ultrasound microbubble intensifier. J Int Med Res. 2010;38:1005-15.
13. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med. 2009;59:339-43.
14. Sung JH, Yang HM, Park JB, Choi GS, Joh JW, Kwon CH, et al. Isolation and characterization of mouse mesenchymal stem cells. Transplant Proc. 2008;40:2649-54.
15. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739-49. (Pubitemid 350127858)
16. + hematopoietic stem cells with bis-pecific antibodies to injured myocardium. Blood Cells Mol Dis. 2004;32:82-7. (Pubitemid 38147701)
17. + hematopoietic stem cells with anti-CD45 X anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction. J Appl Physiol. 2008;104:1793-800.
18. Kraitchman DL, Tatsumi M, Gilson WD, Ishimori T, Kedziorek D, Walczak P, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation. 2005;112:1451-61. (Pubitemid 41291771)
19. Wang Z, Liao Y, Dong J, Li S, Wang J, Fu ML. Clinical significance and pathogenic role of anti-cardiac myosin autoantibody in dilated cardiomyopathy. Chin Med J (Engl). 2003; 116:499-502. (Pubitemid 36675845)
20. Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuh-macher J, Strauss G, et al. Treatment of human B cell lymphoma xenografts with a CD3 X CD19 diabody and T cells. J Immunol. 2000;165:888-95. (Pubitemid 30484756)
21. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. A human tumor xenograft modelof therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 1993;53:94-100. (Pubitemid 23019382)
22. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics. I. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood. 2009;113:6161-71.
23. Marmottant P, Hilgenfeldt S. Controlled vesicle deformation and lysis by single oscillating bubbles. Nature. 2003;423: 153-6. (Pubitemid 36569534)
24. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000;275:10002-8. (Pubitemid 30202047)
25. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006;12:459-65.
26. Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, et al. Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Pfl ugers Arch. 2006;453:43-52. (Pubitemid 44454886)
27. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-8. (Pubitemid 40562318)
28. Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S, et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol- induced global heart failure. Transpl Int. 2008;21:1181-9.
29. Molina EJ, Palma J, Gupta D, Torres D, Gaughan JP, Houser S, et al. Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy. J Tissue Eng Regen Med. 2009;3:85-91.
30. Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC. Extracellular matrix remodeling attenuated after experimental postin-farct left ventricular aneurysm repair. Ann Thorac Surg. 2008; 86:1243-9.
31. Dixon JA, Gorman RC, Stroud RE, Bouges S, Hirotsugu H, Gorman JH 3rd, et al. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009;120:S220-9.
32. Mias C, Lairez O, Trouche E, Roncalli J, Calise D, Seguelas MH, et al. Mesenchymal stem cells promote matrix metal-loproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells. 2009;27:2734-43.
33. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-27.
34. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation. 2007;30:97-104. (Pubitemid 46985774)
35. Wang TL, Yang YH, Chang H, Hung CR. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol. 2004;37:785-94. (Pubitemid 39194570)
36. El-Adawi H, Deng L, Tramontano A, Smith S, Mascareno E, Ganguly K, et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res. 2003;57:129-38. (Pubitemid 36009444)
37. Wagner M, Siddiqui MA. Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs. 2009;10:928-37.
38. Scarabelli TM, Mariotto S, Abdel-Azeim S, Shoji K, Darra E, Stephanou A, et al. Targeting STAT1 by myricetin and del-phinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. FEBS Lett. 2009;583: 531-41.
39. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther. 2008;120:172-85.
40. Barry SP, Townsend PA, McCormick J, Knight RA, Scarabelli TM, Latchman DS, et al. STAT3 deletion sensitizes cells to oxidative stress. Biochem Biophys Res Commun. 2009;385: 324-9.
41. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med. 2005;11:305-11. (Pubitemid 40460559)
42. Ng DC, Court NW, dos Remedios CG, Bogoyevitch MA. Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. Cardiovasc Res. 2003;57:333-46. (Pubitemid 36144212)
43. Fu X, Han B, Cai S, Lei Y, Sun T, Sheng Z. Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor-alpha and its possible role in wound healing. Wound Repair Regen. 2009;17:185-91.
44. Staley BK, Irvine KD. Warts and Yorkie mediate intestinal regeneration by infl uencing stem cell proliferation. Curr Biol. 2010;20:1580-7.
45. Sze SK, de Kleijn DP, Lai RC, Khia Way Tan E, Zhao H, Yeo KS, et al. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol Cell Proteomics. 2007;6:1680-9. (Pubitemid 350031670)
46. Erices A, Conget P, Rojas C, Minguell JJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances oste-oblastic differentiation of human bone marrow-derived mes-enchymal stem cells. Exp Cell Res. 2002;280:24-32. (Pubitemid 35230364)
47. Furlani D, Li W, Pittermann E, Klopsch C, Wang L, Knopp A, et al. A transformed cell population derived from cultured mesenchymal stem cells has no functional effect after transplantation into the injured heart. Cell Transplant. 2009;18: 319-31.